At 36.8x earnings with a Forward P/E of 19.9, the market is clearly pricing in a material earnings acceleration, yet the PEG Forward of 3.3 suggests investors are already paying a premium for that growth. The Altman Z-Score of 3 signals low bankruptcy risk, and a Piotroski F-Score of 9 confirms strong fundamental health, so this is not a distressed balance sheet story. However, with a Price/Sales of 6.9 and Price/Book of 8, valuation leaves little margin for error despite a 23.40% operating margin and 11.60% ROIC. This is not deep value; it’s a quality compounder priced for execution perfection, and the mispricing question hinges entirely on whether the forward multiple compression materializes through earnings delivery.